Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma.

摘要: Abstract Purpose To analyze, in a prospective clinical trial, the efficacy and toxicity of concurrent radiotherapy chemotherapy with gemcitabine cisplatin patients incompletely (R1) resected pancreatic cancer. Methods materials Between 2000 2002, total 30 cancer were treated. Radiotherapy was performed 15 up to dose 45.0 Gy. An additional received 50.0 Gy according International Commission on Radiation Units Measurements (ICRU) Report 50 reference point (equivalent at isodose, including 90% covering former tumor area local lymph nodes). Concurrent radiotherapy, four applications (300 mg/m 2 ) (30 administered. After chemoradiotherapy, courses (1000 (50 Days 1 4-week cycle. Results The median progression-free survival 10.6 months, overall 22.8 months. 1-, 2-, 3-year rate 81%, 43%, 26%, respectively. completion distant metastasis observed 14 during follow-up 15.0 months (range, 4.6–30.0). One patient developed both recurrence metastases. Hematologic toxicities most prominent side effects (leukopenia Grade 3 4 53% 7% thrombocytopenia 33% patients, respectively). GI not observed. Conclusion Postoperative chemoradiotherapy after incomplete resection carcinoma is safe feasible. A prolonged suggests high efficacy, translating into benefit survival. On basis favorable outcome receiving gemcitabine/cisplatin-based testing this combined treatment strategy appears warranted comparative trial.